| Patent Number |
Title Of Patent |
Date Issued |
| 5876830 |
Method of assembly of molecular-sized nets and scaffolding |
March 2, 1999 |
| The present invention relates to methods and starting materials for forming molecular-sized grids or nets, or other structures based on such grids and nets, by creating molecular links between elementary molecular modules constrained to move in only two directions on an interface or surf |
| 5808743 |
Laser sensor using optical feedback-induced frequency modulation |
September 15, 1998 |
| This invention provides an inexpensive, sensitive sensor to measure target position, velocity and vibration based on optical feedback-induced fluctuations in the operating frequency of a diode laser. The sensor comprises a diode laser, an optical frequency discriminator to measure the |
| 5781268 |
Polarization-insensitive fabry-perot tunable filter |
July 14, 1998 |
| This invention provides polarization-independent optical filters that are Fabry-Perot filters. The inventive filters incorporate a phase modulator within the FP cavity and two quarter-wave plates, one on either side of the phase modulator, in the cavity. The quarter-wave plates are p |
| 5731470 |
Weakly nucleophilic anions |
March 24, 1998 |
| Substituted borate and carborate anions having unusual properties of being exceptionally weakly nucleophilic and being soluble in non-polar solvents. One-electron oxidation of the anions yields the corresponding radicals. The compounds are useful, e.g., as electrolytes, catalysts, and |
| 5670545 |
Method for the treatment of ischemic disease and reperfusion injury and the prevention of the ad |
September 23, 1997 |
| Bucillamine and N-2,2-dimethyl-3-mercaptopropionyl)-L-cysteine or related compounds can be used to prevent damage to living tissue from the formation or presence of reactive oxygen species. These reactive oxygen species are formed when tissue is first rendered hypoxic due to interrup |
| 5669914 |
Rotation alignment instrument |
September 23, 1997 |
| This invention provides a rotation alignment device for aligning the tibia with the femur of a patient prior to placement of prosthetic knee components. The device allows the patient's normal, habitual rotation of the tibia with respect to the femur to be preserved when the prosthesis is |
| 5658490 |
Liquid crystal achromatic compound retarder |
August 19, 1997 |
| This invention provides achromatic liquid crystal compound retarders, achromatic polarization switches, and achromatic shutters using the liquid crystal compound retarders. It further provides achromatic variable retardance smectic liquid crystal retarders. The compound retarder of this |
| 5646177 |
Glutathione derivatives of anthracyclines |
July 8, 1997 |
| Disclosed herein are new anthracyclines which are derived from conjugation with glutathione, for example from conjugation of adriamycin, daunomycin and menogaril with glutathione: compounds 7 I, 7 II, 8 I, 8 II, 9 I and 9II, are obtained by reduction of the anthracycline followed by reac |
| 5627666 |
Liquid crystal phase modulator using cholesteric circular polarizers |
May 6, 1997 |
| This invention provides a phase modulator comprising an electro-optically rotatable smectic liquid crystal half-wave retarder in combination with a cholesteric liquid crystal circular polarizer. Rotation of the half-wave retarder varies the phase delay of the modulator. A polarizing |
| 5561287 |
Dual photodetector for determining peak intensity of pixels in an array using a winner take all |
October 1, 1996 |
| A semiconductor device comprising a dual photodetector for use in an array to locate points of peak intensities incident upon the array. Each pixel in the array is comprised of a dual photodetector element. An n-type well is located within a p-substrate with highly doped p-contact areas |
| 5552912 |
Chiral smectic liquid crystal optical modulators |
September 3, 1996 |
| The present invention provides optical modulators which comprise aligned chiral smectic liquid crystal cells within an optical resonance cavity. The cavity configurations include symmetric and asymmetric Fabry-Perot etalons. The liquid crystal cells can be planar- or homeotropically- |
